Skip to main content
Premium Trial:

Request an Annual Quote

Cofactor Genomics, Novocraft Technologies Partner in Southeast Asia

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The sequencing service provider Cofactor Genomics and the bioinformatics company Novocraft Technologies plan to partner to offer sequencing and analysis services in Southeast Asia, Cofactor announced today.

Through the partnership, St. Louis-based Cofactor will offer sequencing services in Southeast Asia and Kuala Lumpur-based Novocraft will provide analyses to support this sequencing effort.

Cofactor, which launched in 2008, uses Illumina and Applied Biosystems sequencing technology combined with commercial and proprietary analysis software, while Novocraft develops novel algorithms for analyzing high throughput sequencing data.

"Southeast Asia is an important emerging market for genome sequencing and analysis and Novocraft's influence in that region will play a fundamental role in helping Cofactor reach our goals," Jon Armstrong, chief marketing officer for Cofactor, said in a statement, noting that the company is already using some Novocraft tools in-house.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.